• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

致 Gomez 等人对 Johnna Perdrizet 等人文章的回应的回复信。

Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.

机构信息

Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.

Health Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil.

出版信息

Hum Vaccin Immunother. 2022 Dec 31;18(1):1917237. doi: 10.1080/21645515.2021.1917237. Epub 2021 Apr 28.

DOI:10.1080/21645515.2021.1917237
PMID:33908816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8942431/
Abstract

This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study "Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants." Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment.

摘要

本通讯旨在回应 Gomez 及其同事在他们对我们原始研究“在巴西婴儿中用 13 价肺炎球菌结合疫苗（PCV13）替代 10 价肺炎球菌结合疫苗（PCV10）的成本效益分析”的信函中提出的问题和批评。Gomez 及其同事担心我们模型中使用的假设可能会对巴西的决策产生意想不到的负面影响，我们打算澄清对我们评估的任何潜在误解。

相似文献

1
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.致 Gomez 等人对 Johnna Perdrizet 等人文章的回应的回复信。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1917237. doi: 10.1080/21645515.2021.1917237. Epub 2021 Apr 28.
2
Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".对约翰娜·佩德里泽特等人所著文章《巴西婴儿用13价肺炎球菌结合疫苗（PCV13）替代10价肺炎球菌结合疫苗（PCV10）的成本效益分析》的回应
Hum Vaccin Immunother. 2022 Dec 31;18(1):1894898. doi: 10.1080/21645515.2021.1894898. Epub 2021 May 19.
3
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".评论戈麦斯等人的文章“对 Wasserman 等人（2018 年）文章的回应：对墨西哥使用 13 价肺炎球菌结合疫苗替代 10 价疫苗的持续使用进行建模”。
Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.
4
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.在巴西婴儿中用13价肺炎球菌结合疫苗（PCV13）替代10价肺炎球菌结合疫苗（PCV10）的成本效益分析。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1162-1172. doi: 10.1080/21645515.2020.1809266. Epub 2020 Sep 23.
5
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.加拿大 13 价和 10 价肺炎球菌结合疫苗 2+1 剂量接种的成本效益。
BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.
6
Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.丹麦和瑞典 10 价与 13 价肺炎球菌结合疫苗的成本效益分析。
Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.
7
Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.在韩国，13价肺炎球菌结合疫苗与10价肺炎球菌结合疫苗的国家免疫规划的成本效益比较。
Hum Vaccin Immunother. 2021 Mar 4;17(3):909-918. doi: 10.1080/21645515.2020.1796426. Epub 2020 Aug 12.
8
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.13 价肺炎球菌结合疫苗的成本效益：德国、希腊和荷兰。
J Infect. 2012 Jan;64(1):54-67. doi: 10.1016/j.jinf.2011.10.015. Epub 2011 Nov 4.
9
Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.对吴等人的回应——马来西亚和香港婴儿肺炎球菌疫苗接种的成本效益分析
Hum Vaccin Immunother. 2016 Oct 2;12(10):2675-2680. doi: 10.1080/21645515.2016.1192738. Epub 2016 Jul 26.
10
Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.马来西亚和香港地区婴儿普遍常规接种肺炎球菌疫苗的成本效益分析。
Hum Vaccin Immunother. 2016;12(2):403-16. doi: 10.1080/21645515.2015.1067351.

引用本文的文献

1
Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".对戈麦斯等人就《13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益》致编辑信的回复。
Infect Dis Ther. 2022 Aug;11(4):1763-1765. doi: 10.1007/s40121-022-00641-9. Epub 2022 May 16.

本文引用的文献

1
Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia.澳大利亚肺炎球菌结合疫苗婴儿计划的回顾性影响分析及成本效益
Infect Dis Ther. 2021 Mar;10(1):507-520. doi: 10.1007/s40121-021-00409-7. Epub 2021 Feb 11.
2
Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.7 价和 13 价肺炎球菌结合疫苗预防疫苗血清型中耳炎的效果。
Clin Infect Dis. 2021 Aug 16;73(4):650-658. doi: 10.1093/cid/ciab066.
3
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.评估在哥伦比亚、芬兰和荷兰从低价次向高价次肺炎球菌结合疫苗转换的影响：一项成本效益分析。
Infect Dis Ther. 2020 Jun;9(2):305-324. doi: 10.1007/s40121-020-00287-5. Epub 2020 Feb 24.
4
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.评估在意大利从13价肺炎球菌结合疫苗（PCV13）转换为10价肺炎球菌结合疫苗（PCV10）的临床和经济影响。
Pathogens. 2020 Jan 22;9(2):76. doi: 10.3390/pathogens9020076.
5
Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.在马来西亚引入肺炎球菌结合疫苗的人群健康和经济影响评估- 经济评价。
Hum Vaccin Immunother. 2020 Jul 2;16(7):1719-1727. doi: 10.1080/21645515.2019.1701911. Epub 2020 Jan 17.
6
Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.建立模型以比较 13 价肺炎球菌结合疫苗在墨西哥的持续使用与切换至 10 价疫苗的情况。
Hum Vaccin Immunother. 2019;15(3):560-569. doi: 10.1080/21645515.2018.1516491. Epub 2018 Sep 21.
7
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.加拿大13价肺炎球菌结合疫苗转为10价肺炎球菌结合疫苗用于婴儿接种的潜在临床和经济影响
Infect Dis Ther. 2018 Sep;7(3):353-371. doi: 10.1007/s40121-018-0206-1. Epub 2018 Jun 22.
8
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.肺炎球菌非分型流感嗜血杆菌蛋白 D 结合疫苗（PHiD-CV）在拉丁美洲幼儿中的疗效：一项双盲随机对照试验。
PLoS Med. 2014 Jun 3;11(6):e1001657. doi: 10.1371/journal.pmed.1001657. eCollection 2014 Jun.